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Purpose: To identify the genetic basis of posterior polymorphous corneal dystrophy 1 (PPCD1) using next-generation
sequencing (NGS) of the common PPCD1 support interval, in which Sanger sequencing failed to identify a pathogenic
mutation.
Methods: Enrichment of the portion of chromosome 20 containing the common PPCD1 interval was performed on DNA
extracted from an affected and an unaffected member of a family previously linked to the PPCD1 locus. NGS using the
Roche 454 Titanium platform was performed, followed by computational analysis using NextGENe Software.
Results: NGS of the selectively enriched chromosomal 20 region between markers D20S48 and D20S190 produced over
400,000 DNA sequence reads with an average of 350 bases for each of the two DNA samples. Alignment of the DNA
sequence reads with the reference sequence from the National Center of Biotechnology Information (NCBI) resulted in
over 119 million matched bases per sample. Approximately 68,000 DNA sequence variants were identified in the common
PPCD1 support interval in the affected individual, which was approximately twice the number of sequence variants
identified in the unaffected individual. In both individuals, approximately 0.5% of the identified variants mapped to the
13 known and 16 predicted genes in the PPCD1 support interval, including 16 of the 17 (94%) variants previously identified
by Sanger sequencing in the 13 known genes. In both individuals, the variant not identified by NGS was located in a
region of inadequate coverage.
Conclusions: NGS identified all of the exonic sequence variants that were previously identified by Sanger sequencing in
known genes in adequately covered regions of the common PPCD1 interval, although the pathogenic variant is yet to be
discovered. Given adequate coverage of a selectively enriched chromosomal region of interest, NGS represents a useful
technique to screen for sequence variants in candidate gene loci that has multiple advantages over previously employed
techniques for mutation discovery.
Since the introduction of DNA sequencing in the mid-
seventies  by  Frederick  Sanger  [1],  the  sequencing
methodology that bears his name has enabled researchers to
make significant discoveries and advances in all branches of
biology and medicine, including the sequencing of the human
genome [2]. While Sanger sequencing has been considered
the gold standard for accuracy in generating sequencing data
for over three decades, the development of new sequencing
methods that are less expensive, less laborious and generate
significantly more information in considerably less time have
challenged the supremacy of Sanger sequencing in recent
years.  These  new  methods  are  termed  next  generation
sequencing  (NGS),  characterized  by  massive  parallel
sequencing that produces up to a million reads in one run. NGS
has  been  employed  for  varied  applications  including
resequencing  of  the  human  genome  [2,3],  whole  genome
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resequencing  for  evolutionary  studies  [4,5],  de  novo
sequencing  of  bacterial  genomes  [6],  quantifying  of  rare
transcripts [7], identifying alternative splicing and sequence
variation  [8],  single  nucleotide  polymorphism  (SNP)
discovery [9], and targeted resequencing of specific genetic
loci [10-12].
We have recently reported the absence of coding region
mutations in the positional candidate genes mapped to the
common  posterior  polymorphous  corneal  dystrophy  1
(PPCD1; OMIM 122000) interval [13]. Although screening
of the exonic and intron/exon boundary regions for each of
the known and predicted genes in the common PPCD1 interval
using Sanger sequencing did not reveal a pathogenic mutation,
convincing evidence indicates that the causative mutation(s)
for PPCD1 lie(s) within the 2.4 cM region between markers
D20S182  and  D20S139  that  includes  13  known  and  16
predicted genes (build 37.1) [13]. Given the fact that Sanger
sequencing  may  miss  low  frequency  sequence  variations
[14], and in light of reports of the successful application of
NGS to identify causative mutations in candidate regions of
interest [11,12,15], we sought to determine the utility of NGS
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2829in  identifying  the  genetic  basis  of  PPCD1  following
enrichment of the region of chromosome 20 containing the
common PPCD1 interval.
METHODS
The researchers followed the tenets of the Declaration of
Helsinki in the treatment of the subjects reported herein. Study
approval was obtained from the Institutional Review Board at
the University of California, Los Angeles (UCLA IRB #02–
10–092–11).
Patient identification/DNA collection and isolation: The
diagnosis  of  PPCD  was  based  on  established,  previously
published  criteria  [16].  A  peripheral  blood  sample  was
collected from an affected and an unaffected member of a
family previously linked to the PPCD1 locus, and DNA was
isolated using a commercially-available kit (Flexigene DNA
isolation kit; Qiagen, Valencia, CA).
Sanger  sequencing  of  newly  annotated  genes  in  the
common PPCD1 interval: We have previously reported the
results  of  Sanger  sequencing  of  the  genes  mapped  to  the
common PPCD1 interval (build 36.3) [13]. In the most recent
build (build 37.1), four additional genes have been mapped to
this  interval  (LOC100287054,  cytochrome  c  oxidase
assembly  factor-like  [PET117],  LOC100287095,  and
LOC100270804) and one gene that appeared in the previous
build (36.3) was removed (LOC100130062). Therefore, using
DNA from the same two affected and unaffected individuals
that were the source of DNA in our previous report [13], we
performed PCR amplification of the coding regions of the
recently  annotated  genes  using  custom-designed  primers
(Primer  3;Table  1),  and  Sanger  sequencing  as  described
previously [13].
Sequence capture and enrichment of common PPCD1
interval: A 4.8 Mb region between D20S48 and D20S190 that
contains the 2.4 cM PPCD1 common interval region was
selected for enrichment by the Roche-NimbleGen SeqCap
Service Workflow. A custom Sequence Capture 385K Human
Array was designed and manufactured by Roche NimbleGen
(Madison, WI). A total of 385,000 unique, overlapping probes
were designed across the PPCD1 target region (Chromosome
20: 17,000,000– 21,258,707; NCBI build 36.1, hg18). The
targeted region was tiled so as to avoid capturing repetitive
DNA fragments. Approximately 10 μg of genomic DNA was
fragmented by sonication to a size range of 300–500 base
pairs.  The  fragmented  DNA  was  purified  (AMPure  XP
system; Agencourt Bioscience Corporation, Beverly, MA)
and  analyzed  on  an  Agilent  Bioanalyzer  2100  (Agilent
Technologies,  Santa  Clara,  CA)  according  to  the
manufacturer's instructions. The fragments were then ligated
to universal gSel3 and gSel4 adapters (Roche NimbleGen)
with  T4  DNA  Ligase.  Small  fragments  (<100  bp)  were
removed  with  the  use  of  AMPure  Beads  (Agencourt
Bioscience Corporation). The resulting library was hybridized
to the custom 385K array with the use of the NimbleGen
Sequence Capture Hybridization System. Hybridized DNA
from the PPCD1 target region was washed and eluted with the
use of a NimbleGen Wash and Elution Kit according to the
manufacturer's instructions. The eluted sample was amplified
by  ligation-mediated  PCR  with  the  use  of  primers
complementary to the sequence of the adaptors.
Next-generation  sequencing:  The  selectively  enriched
samples were then sent to Agencourt Bioscience Corporation
for NGS on a 454/FLX Genome Sequencer platform (Roche/
454  Life  Sciences,  Brandford,  CT)  using  the  GS  FLX
Titanium service.
Sequence  assembly  and  analysis:  Sequence  data
generated by the 454 Genome Sequencer was assembled using
NextGENe Software (SoftGenetics, State College, PA) and
aligned to the chromosome 20 reference sequence (NCBI
build 37.1). Each sequence aligned to a particular genomic
region is known as a read, with the number of reads at a certain
region being referred to as coverage (Figure 1). The sequence
data  was  analyzed  on  an  Intel  i7–920  processor  based
computer with 12 GB RAM. For the initial analysis that was
TABLE 1. PRIMERS USED FOR SEQUENCING OF ADDITIONAL GENES MAPPED TO COMMON PPCD1 INTERVAL IN BUILD 37.1.
Gene Exon Forward primer Tm
(ºC)
Reverse primer Tm
(ºC)
Product size (bp)
LOC100270804* 1A gcgtggtaatgtggctttgtacc 68.1 tcaacagtaaacgctgcacatcc 68.1 558
  1B actcgctccttcccgcaaatgta 71.4 ttcttttcagtcgacacatgcaa 66.6 592
  1C ctccctgacagacactggcctta 68.6 ggctacaaagagccccttcttga 68.4 552
  1D aagcggatgacctgtgttcactc 68.6 cggtcctgaggtagggctacagt 68.4 527
  1E agagggtcctgtcatccattgaa 67.8 ccgaactgtaccaaactcatgtgc 68.4 695
LOC100287054 1 gctgttgctgaccagggtgt 67.7 aggctcttctccctcccttgaat 68.2 299
  2 caaaaggacacagaggtgaactgg 67.8 ccatgaccaaccgatgctgt 68.3 486
  3 cacaacattgttccacggtctca 69.1 gcagacagggcagcctcaag 69.7 398
  4 ctggaggggagagggagagaag 68.6 agtagcgccgagaaatccgttac 68.1 395
LOC100287095 1 gcttgtgcctccagaccagaat 68.7 ccaccttggcctcccaaa 68.4 300
  2 ttaaaattgcccaaaacccaagg 68.0 tcacccacgtgcgatatttcttc 68.9 661
PET117 1 ctatgctcggctctcgattgct 68.7 accgcgggggaaagacac 69.6 384
  2 aactgggtatttggaatctgaaa 62.3 tgatcaagtttaaaaggacagtgacca 67.2 394
*The 2017 bp exon of LOC100270804 was amplified and sequenced as 5 overlapping segments.
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2830performed, the default filtering parameters were used with the
Condensation  Tool  (Table  2,  Default  A),  a  proprietary
software tool that employs depth of coverage to lengthen reads
and  statistically  discount  instruments  errors  (such  as
homopolymer  errors  and  base  call  errors  caused  by
pyrosequencing). The data was subsequently analyzed using
the  default  filtering  parameters  without  the  Condensation
Tool (Table 2, Default B). Data analysis included determining
the total number of identified variants, the number of coding
region  variants  in  all  positional  candidate  genes,  and  the
number of exonic sequence variants identified in the known
genes in the common PPCD1 interval, which were compared
to the exonic sequence variants identified in the same genes
by Sanger sequencing. The filtering parameters were then
adjusted to increase the sensitivity of the software to detect
sequence  variants  in  regions  with  coverage  of  ≥5  reads
(defined  as  adequate  coverage)  until  all  exonic  variants
identified  in  the  common  PPCD1  interval  by  Sanger
sequencing  were  also  identified  by  NGS  (Table  2,  Best
Adjusted).
RESULTS
Sanger sequencing of newly annotated genes in the common
PPCD1 interval: Sanger sequencing of the newly annotated
genes in the common PPCD1 interval (build 37.1) revealed
two  novel  and  three  previously  described  SNPs  in
Figure 1. Illustration of pericentromeric region of chromosome 20 to which PPCD1 has been mapped, demonstrating multiple sequence reads
that identify a mutation in the gene LOC100270804. The common PPCD1 interval is shown within the NimbleGen sequence capture target
region as a solid black bar. The bar below it is the tiled region showing breaks where the sequence capture was blocked to prevent binding of
repetitive DNA sequences. Also depicted are genes mapped to the common PPCD1 interval, including LOC100270804, in which a G>T
sequence variant in exon 2 is identified in the heterozygous state.
TABLE 2. NEXT-GENERATION SEQUENCING DEFAULT PARAMETERS RUN WITH AND WITHOUT APPLICATION OF CONDENSATION TOOL AND
BEST ADJUSTED PARAMETERS.
Parameters Default A Default B Best adjusted
Condensation tool Yes No No
Alignment
Seed number 30 30 35
Move step 5 5 10
Matching base percentage 80% 80% 85%
Mutation filter (mutation percentage) 20% 20% 25%
Mutation score (optional) Not applied Not applied Applied, score=5
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2831LOC100270804  (no  variants  were  identified  in
LOC100287054, PET117, or LOC100287095). Two of the
three  known  and  both  of  the  novel  sequence  variants  in
LOC100270804  were  present  in  both  affected  family
members but not in either unaffected family member that was
initially screened. (Figure 1 and Table 3) Screening of nine
additional  affected  family  members,  nine  additional
unaffected  family  members  and  seven  unaffected  spouses
revealed that the minor allele of each of these four SNPs was
present in each of the affected family members and absent in
each of the unaffected family members and six of the spouses.
The spouse in whom the minor allele of each of these four
variants was identified is the same individual in whom the
minor allele of three of the four SNPs that we have previously
reported as segregating with the affected phenotype in this
family were identified [13]. However, none of these SNPs was
considered  disease-causing  as  each  was  identified  in
unaffected control individuals.
Sequence  capture  and  next  generation  sequencing  of  the
PPCD1 common interval: Greater than 400,000 reads were
obtained  from  each  of  the  two  DNA  samples  that  were
captured and sequenced, with an average read length of 350
bases. Approximately 80% of the reads mapped to the human
genome, 35% of which mapped to the selectively enriched
common PPCD1 interval, and about 20% of the reads did not
match to the genome due to one or more factors, including the
stringency  of  alignment  settings.  Alignment  of  the  DNA
sequence reads with the NCBI reference sequence resulted in
at least 119 million matched bases from each sample. The
average sequence coverage of the common PPCD1 interval
was 28 fold for the affected individual and 19-fold for his
unaffected son. Sequencing coverage of the 29 known and
predicted genes (build 37.1) in the common PPCD1 interval
varied  significantly  for  the  affected  and  unaffected
individuals, ranging from zero to 70 fold.
Sequence  analysis  using  default  parameters  with
Condensation  Tool:  Using  the  default  parameters  with
Condensation Tool (Table 2, Default A), 430,175 matched
reads were obtained in the affected individual’s DNA sample.
A total of 67,599 DNA sequence variants were identified in
the common PPCD1 support interval, of which 0.46% (311)
were in the coding region of the 13 known genes. In the
unaffected individual’s DNA sample, 370,400 matched reads
were obtained, containing 27,448 DNA sequence variants in
the common PPCD1 support interval, of which 0.56% (154)
were  coding  region  variants  in  the  13  known  genes.
NextGENe software was not able to distinguish intronic from
exonic variants in the predicted genes as the entirety of the
predicted genes was considered to be part of the non-coding
sequence.
To determine the sensitivity of NGS, the sequence data
generated by Sanger sequencing was compared to sequence
data generated by NGS to determine what percentage of the
exonic sequence variants identified in the 13 known genes and
16  predicted  genes  in  the  common  PPCD1  interval  with
Sanger sequencing of the affected and unaffected individual’s
DNA were identified with NGS. Eleven of the 17 (69%)
exonic  sequence  variants  previously  identified  by  Sanger
sequencing in known genes were identified in the affected
individual with NGS. While two variants (c.52_54delCGC in
SLC24A3 and c.846T>C in C20orf72) were not reported due
to insufficient coverage (less than 5 reads), four variants were
not identified by NGS, even though they were located in
regions of adequate coverage. Of the 28 exonic sequence
variants identified in the 16 predicted genes, only 5 (17%)
were identified by NGS. Nineteen of the remaining 23 variants
were not identified due to insufficient coverage, while four
were located in regions of adequate coverage but were not
identified.
In the unaffected individual, NGS detected 14 of the 17
(82%) exonic variants identified by Sanger sequencing in the
13 known genes mapped to the common PPCD1 interval. Two
of the three unidentified variants were located in regions of
adequate coverage, while the other variant (c.52_54delCGC
in SLC24A3) was not reported due to insufficient coverage.
Of  the  25  exonic  sequence  variants  identified  by  Sanger
sequencing in the 16 predicted genes, only two (8%) were
identified by NGS. Nineteen of the remaining 23 variants were
not identified due to insufficient coverage while four were
located  in  regions  of  adequate  coverage  but  were  not
identified.
Sequence  analysis  using  default  parameters  without
Condensation Tool: Using the default parameters without the
Condensation Tool (Table 2, Default B), 429,484 matched
reads were obtained in the affected individual’s DNA sample.
A total of 67,986 DNA sequence variants were identified in
the common PPCD1 support interval, of which 0.53% (357)
were coding region variants. In the unaffected individual’s
DNA sample, 370,627 matched reads were obtained, in which
34,419 DNA sequence variants were identified in the common
PPCD1 support interval, of which 0.54% (185) were coding
region  variants.  In  both  the  affected  and  the  unaffected
individual,  94%  (16/17)  of  the  exonic  sequence  variants
identified  by  Sanger  sequencing  in  the  13  known  coding
region genes mapped to the common PPCD1 interval were
identified  by  NGS.  In  both  individuals,  the  variant  not
identified by NGS was c.52_54delCGC in SLC24A3, which
was located in a region of inadequate coverage. The other
identified  discrepancy  between  Sanger  and  NGS  was  the
identification of the known SNP c.1410 G>C (rs6075337) in
C20orf12 in the heterozygous state by Sanger sequencing and
in the homozygous state by NGS. Manual re-analysis of the
reads generated by the NextGENe software revealed coverage
of 34 reads at this base, with guanine present in 2 reads and
cytosine present in the remaining 32 reads. Due to this 1:16
ratio,  NextGENe  software  identified  this  variant  as
homozygous.
Molecular Vision 2010; 16:2829-2838 <http://www.molvis.org/molvis/v16/a303> © 2010 Molecular Vision
2832T
A
B
L
E
 
3
.
 
S
E
Q
U
E
N
C
E
 
V
A
R
I
A
N
T
S
 
A
S
 
I
D
E
N
T
I
F
I
E
D
 
B
Y
 
S
A
N
G
E
R
 
S
E
Q
U
E
N
C
I
N
G
 
I
N
 
C
A
N
D
I
D
A
T
E
 
G
E
N
E
S
 
W
I
T
H
I
N
 
T
H
E
 
C
O
M
M
O
N
 
P
P
C
D
1
 
O
F
 
B
U
I
L
D
 
3
7
.
1
 
A
N
D
 
T
H
E
I
R
 
A
P
P
E
A
R
A
N
C
E
 
I
N
 
D
A
T
A
 
G
E
N
E
R
A
T
E
D
 
B
Y
 
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
S
E
Q
U
E
N
C
I
N
G
 
(
N
G
S
)
.
 
 
 
 
N
e
x
t
-
g
e
n
e
r
a
t
i
o
n
 
s
e
q
u
e
n
c
i
n
g
S
a
n
g
e
r
 
s
e
q
u
e
n
c
i
n
g
G
e
n
e
 
(
r
e
f
S
e
q
)
N
u
c
l
e
o
t
i
d
e
 
c
h
a
n
g
e
A
m
i
n
o
 
a
c
i
d
 
c
h
a
n
g
e
 
 
 
 
 
 
 
 
 
 
r
e
f
S
N
P
 
I
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
f
f
e
c
t
e
d
U
n
a
f
f
e
c
t
e
d
A
f
f
e
c
t
e
d
U
n
a
f
f
e
c
t
e
d
S
N
X
5
 
(
N
M
_
1
5
2
2
2
7
)
c
.
5
4
3
G
>
A
p
.
G
l
u
1
8
1
G
l
u
r
s
2
2
7
3
4
4
8
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
5
Y
 
(
h
e
t
e
r
o
)
Y
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
S
N
O
R
D
1
7
(
N
R
_
0
0
3
0
4
5
)
9
8
T
>
A
N
o
n
-
c
o
d
i
n
g
 
m
i
c
r
o
R
N
A
r
s
7
5
3
2
1
3
N
Y
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
1
N
Y
 
(
h
e
t
e
r
o
)
C
2
0
o
r
f
7
2
 
(
N
M
_
0
1
8
1
5
2
)
c
.
4
3
A
>
T
p
.
S
e
r
1
5
C
y
s
r
s
1
1
5
5
1
7
6
8
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
8
N
Y
 
(
h
e
t
e
r
o
)
N
 
c
.
7
9
4
C
>
T
p
.
T
h
r
2
6
5
I
l
e
-
N
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
*
*
N
Y
 
(
h
e
t
e
r
o
)
 
c
.
8
4
6
T
>
C
p
.
A
s
p
2
8
2
A
s
p
r
s
2
8
4
5
5
0
9
1
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
*
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
9
Y
 
(
h
e
t
e
r
o
)
Y
(
h
e
t
e
r
o
)
P
T
M
A
P
3
 
(
N
G
_
0
0
1
1
8
0
)
c
.
3
4
7
T
>
G
p
.
V
a
l
1
1
6
G
l
y
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
3
4
8
C
>
G
p
.
V
a
l
1
1
6
V
a
l
-
N
*
N
*
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
 
c
.
3
6
2
C
>
G
p
.
T
h
r
1
2
1
A
r
g
-
N
*
N
*
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
 
c
.
4
1
5
T
>
C
p
.
L
e
u
1
3
9
L
e
u
-
N
*
N
*
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
 
c
.
5
5
3
T
>
C
p
.
C
y
s
1
8
5
A
r
g
r
s
3
7
4
8
4
9
3
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
o
m
o
)
 
c
.
8
4
3
C
>
T
p
.
C
y
s
2
8
1
C
y
s
r
s
3
7
4
8
4
9
2
N
*
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
4
*
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
o
m
o
)
L
O
C
1
0
0
2
8
7
0
5
4
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
O
V
O
L
2
 
(
N
M
_
0
2
1
2
2
0
)
c
.
3
2
7
C
>
A
p
.
T
h
r
1
0
9
T
h
r
r
s
6
1
1
1
8
0
3
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
7
N
Y
 
(
h
e
t
e
r
o
)
N
R
P
L
1
5
P
1
 
(
N
G
_
0
0
0
9
7
5
)
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
P
E
T
1
1
7
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
C
S
R
P
2
B
P
 
(
N
M
_
0
2
0
5
3
6
)
c
.
1
1
9
9
T
>
G
p
.
V
a
l
4
0
0
G
l
y
r
s
1
2
0
5
1
9
3
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
3
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
1
8
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
 
c
.
1
4
3
7
C
>
T
p
.
P
r
o
4
7
9
P
r
o
r
s
1
2
0
5
1
9
4
N
N
N
N
 
c
.
1
4
9
9
C
>
T
p
.
A
l
a
5
0
0
V
a
l
r
s
4
1
2
7
6
4
1
8
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
5
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
1
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
2
2
2
3
T
>
C
p
.
P
r
o
7
4
1
P
r
o
r
s
2
7
4
7
4
0
4
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
5
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
1
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
L
O
C
1
0
0
2
8
7
0
9
5
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
Z
N
F
1
3
3
 
(
N
M
_
0
0
3
4
3
4
)
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
M
G
C
4
4
3
2
8
(
N
M
_
0
0
1
0
0
4
3
4
4
)
c
.
8
9
T
>
C
p
.
L
e
u
3
0
P
r
o
r
s
1
8
8
3
9
3
8
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
7
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
0
Y
 
(
h
o
m
o
)
Y
(
h
o
m
o
)
C
2
0
o
r
f
1
2
 
(
N
M
_
0
1
8
1
5
2
)
c
.
4
0
T
>
C
p
.
L
e
u
1
4
L
e
u
r
s
6
0
3
5
0
5
1
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
5
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
5
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
o
m
o
)
 
c
.
8
0
1
T
>
C
p
.
C
y
s
2
6
7
C
y
s
r
s
6
0
3
5
0
4
2
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
9
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
3
Y
 
(
h
o
m
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
1
4
1
0
G
>
C
p
.
L
e
u
4
7
0
L
e
u
r
s
6
0
7
5
3
3
7
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
6
Y
 
(
h
o
m
o
)
+
S
c
o
r
e
=
2
1
Y
 
(
h
o
m
o
)
Y
(
h
e
t
e
r
o
)
 
+
Molecular Vision 2010; 16:2829-2838 <http://www.molvis.org/molvis/v16/a303> © 2010 Molecular Vision
2833G
e
n
e
 
(
r
e
f
S
e
q
)
N
u
c
l
e
o
t
i
d
e
 
c
h
a
n
g
e
A
m
i
n
o
 
a
c
i
d
 
c
h
a
n
g
e
 
 
 
 
 
 
 
 
 
 
r
e
f
S
N
P
 
I
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
f
f
e
c
t
e
d
U
n
a
f
f
e
c
t
e
d
A
f
f
e
c
t
e
d
U
n
a
f
f
e
c
t
e
d
G
C
N
T
1
P
 
(
N
G
_
0
0
1
0
3
9
)
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
P
O
L
R
3
F
 
(
N
M
_
0
0
6
4
6
6
)
c
.
8
4
0
A
>
G
p
.
T
h
r
2
8
0
T
h
r
r
s
1
0
5
5
1
7
1
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
6
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
3
Y
 
(
h
o
m
o
)
Y
 
(
h
e
t
e
r
o
)
R
P
L
2
1
P
3
 
(
N
G
_
0
0
0
9
7
6
)
c
.
3
4
6
d
e
l
A
p
.
A
r
g
1
1
6
G
l
y
f
s
X
2
8
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
R
B
B
P
9
 
(
N
M
_
0
0
6
6
0
6
)
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
R
P
S
1
9
P
1
 
(
N
G
_
0
0
1
2
9
5
)
c
.
1
3
6
C
>
G
p
.
P
r
o
4
6
A
l
a
r
s
2
0
0
9
0
9
2
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
2
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
5
Y
 
(
h
o
m
o
)
Y
 
h
e
t
e
r
o
)
 
c
.
1
6
7
G
>
A
p
.
A
r
g
5
6
G
l
n
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
N
S
E
C
2
3
B
 
(
N
M
_
0
3
2
9
8
5
)
c
.
4
9
0
G
>
A
p
.
V
a
l
1
6
4
M
e
t
r
s
3
6
0
2
3
1
5
0
N
N
N
N
 
c
.
1
1
9
8
T
>
C
p
.
P
h
e
4
0
0
L
e
u
-
N
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
8
N
Y
(
h
e
t
e
r
o
)
 
c
.
1
2
7
6
G
>
A
p
.
V
a
l
4
2
6
I
l
e
-
N
N
N
N
 
c
.
1
4
6
7
C
>
G
p
.
H
i
s
4
8
9
G
l
n
r
s
2
2
7
3
5
2
6
N
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
7
N
Y
(
h
e
t
e
r
o
)
L
O
C
3
8
8
7
8
9
(
X
M
_
9
3
9
9
5
4
)
c
.
4
8
A
>
G
p
.
A
r
g
1
6
A
r
g
r
s
1
2
6
2
4
9
3
5
N
*
N
*
N
Y
 
(
h
e
t
e
r
o
)
D
T
D
1
 
(
N
M
_
0
8
0
8
2
0
)
N
o
 
C
h
a
n
g
e
s
 
 
 
 
 
 
D
U
X
A
P
7
 
(
N
G
_
0
0
4
8
4
6
)
c
.
4
4
7
A
>
C
p
.
G
l
n
1
4
9
H
i
s
r
s
6
1
3
2
0
9
4
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
6
6
4
A
>
G
p
.
T
h
r
2
2
2
A
l
a
r
s
6
0
8
1
2
7
1
N
*
N
*
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
 
c
.
6
6
5
C
>
T
p
.
T
h
r
2
2
2
I
l
e
r
s
6
0
8
1
2
7
0
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
7
1
6
T
>
A
p
.
I
l
e
2
3
9
L
y
s
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
7
1
9
d
e
l
A
p
.
L
y
s
2
4
0
L
y
s
f
s
X
3
9
-
N
*
N
*
N
Y
 
(
h
e
t
e
r
o
)
 
c
.
7
2
0
d
e
l
A
p
.
L
y
s
2
4
0
L
y
s
f
s
X
3
9
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
7
2
1
i
n
s
A
p
.
G
l
u
2
4
1
A
r
g
f
s
X
2
5
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
7
2
6
_
7
3
0
d
u
p
G
A
A
A
A
p
.
A
r
g
2
4
4
A
r
g
f
s
X
3
7
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
7
2
6
_
7
3
0
d
u
p
G
A
A
A
A
 
[
3
]
p
.
A
r
g
2
4
4
A
r
g
f
s
X
2
5
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
9
4
3
G
>
C
p
.
V
a
l
3
1
5
L
e
u
r
s
6
1
3
2
0
9
3
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
1
1
2
4
T
>
C
p
.
V
a
l
3
7
5
A
l
a
r
s
6
0
8
1
2
6
8
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
 
c
.
1
1
5
6
C
>
T
p
.
P
r
o
3
8
6
S
e
r
r
s
6
0
7
5
3
8
2
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
L
O
C
1
0
0
1
3
2
3
5
8
(
N
C
_
0
0
0
0
2
0
)
c
.
2
7
4
C
>
T
p
.
G
l
n
9
2
X
r
s
6
0
8
1
3
6
9
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
4
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
6
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
H
S
P
C
0
7
2
 
(
A
F
1
6
1
5
5
7
)
N
o
 
C
h
a
n
g
e
s
L
O
C
1
0
0
2
7
0
8
0
4
1
7
2
C
>
T
p
.
P
r
o
5
8
S
e
r
r
s
4
1
3
0
9
8
3
1
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
3
N
Y
 
(
h
e
t
e
r
o
)
N
c
.
5
4
3
G
>
T
p
.
G
l
y
1
8
1
G
l
y
r
s
7
2
6
2
3
2
0
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
6
N
Y
 
(
h
e
t
e
r
o
)
N
6
8
5
_
6
8
6
i
n
s
G
p
.
 
G
l
u
2
2
9
f
x
X
2
3
-
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
4
N
Y
 
(
h
e
t
e
r
o
)
N
1
3
4
3
G
>
A
p
.
A
r
g
4
4
8
A
r
g
r
s
8
0
0
4
6
3
3
6
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
2
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
7
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
1
3
6
0
_
1
3
6
4
d
e
l
A
A
G
A
A
p
.
L
y
s
4
8
4
f
s
X
1
8
-
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
5
N
Y
(
h
e
t
e
r
o
)
N
Molecular Vision 2010; 16:2829-2838 <http://www.molvis.org/molvis/v16/a303> © 2010 Molecular Vision
2834
T
A
B
L
E
 
3
.
 
S
E
Q
U
E
N
C
E
 
V
A
R
I
A
N
T
S
 
A
S
 
I
D
E
N
T
I
F
I
E
D
 
B
Y
 
S
A
N
G
E
R
 
S
E
Q
U
E
N
C
I
N
G
 
I
N
 
C
A
N
D
I
D
A
T
E
 
G
E
N
E
S
 
W
I
T
H
I
N
 
T
H
E
 
C
O
M
M
O
N
 
P
P
C
D
1
 
O
F
 
B
U
I
L
D
 
3
7
.
1
 
A
N
D
 
T
H
E
I
R
 
A
P
P
E
A
R
A
N
C
E
 
I
N
 
D
A
T
A
 
G
E
N
E
R
A
T
E
D
 
B
Y
 
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
S
E
Q
U
E
N
C
I
N
G
 
(
N
G
S
)
.
 
 
 
 
N
e
x
t
-
g
e
n
e
r
a
t
i
o
n
 
s
e
q
u
e
n
c
i
n
g
S
a
n
g
e
r
 
s
e
q
u
e
n
c
i
n
gG
e
n
e
 
(
r
e
f
S
e
q
)
N
u
c
l
e
o
t
i
d
e
 
c
h
a
n
g
e
A
m
i
n
o
 
a
c
i
d
 
c
h
a
n
g
e
 
 
 
 
 
 
 
 
 
 
 
r
e
f
S
N
P
 
I
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
f
f
e
c
t
e
d
U
n
a
f
f
e
c
t
e
d
A
f
f
e
c
t
e
d
U
n
a
f
f
e
c
t
e
d
L
O
C
1
0
0
1
2
8
4
9
6
(
X
M
_
0
0
1
7
2
5
7
0
5
)
c
.
1
3
8
C
>
G
p
.
L
e
u
4
6
L
e
u
r
s
5
6
7
4
3
2
7
1
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
9
N
Y
 
(
h
e
t
e
r
o
)
N
C
2
0
o
r
f
7
9
 
(
N
M
_
1
7
8
4
8
3
)
c
.
2
5
5
C
>
T
p
.
T
h
r
8
5
T
h
r
r
s
1
0
5
3
8
3
4
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
5
N
Y
 
(
h
e
t
e
r
o
)
N
c
.
2
9
5
C
>
T
p
.
P
r
o
9
9
S
e
r
r
s
1
0
5
3
8
3
9
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
2
0
N
Y
 
(
h
e
t
e
r
o
)
N
S
L
C
2
4
A
3
 
(
N
M
_
0
2
0
6
8
9
)
c
.
5
2
_
5
4
d
e
l
C
G
C
*
p
.
A
r
g
1
8
d
e
l
-
N
*
N
*
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
e
t
e
r
o
)
c
.
1
6
3
G
>
A
p
.
V
a
l
5
5
I
l
e
r
s
1
5
6
9
7
6
7
N
Y
 
(
h
e
t
e
r
o
)
S
c
o
r
e
=
1
7
N
Y
 
(
h
e
t
e
r
o
)
c
.
3
6
9
G
>
A
p
.
A
l
a
1
2
3
A
l
a
r
s
3
7
9
0
2
6
1
Y
 
(
H
e
t
e
r
o
)
S
c
o
r
e
=
2
6
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
4
Y
 
(
h
e
t
e
r
o
)
Y
 
(
h
o
m
o
)
c
.
6
3
9
G
>
A
p
.
L
e
u
2
1
3
L
e
u
r
s
3
7
9
0
2
7
8
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
3
0
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
1
5
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
c
.
6
5
4
T
>
C
p
.
I
l
e
2
1
8
I
l
e
r
s
3
7
9
0
2
7
9
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
6
Y
 
(
h
o
m
o
)
S
c
o
r
e
=
2
3
Y
 
(
h
o
m
o
)
Y
 
(
h
o
m
o
)
L
O
C
1
0
0
1
3
0
2
6
4
(
X
M
_
0
0
1
7
1
7
9
6
2
)
N
o
 
C
h
a
n
g
e
s
M
u
t
a
t
i
o
n
 
s
c
o
r
e
 
i
s
 
p
r
o
v
i
d
e
d
 
f
o
r
 
a
l
l
 
N
G
S
 
i
d
e
n
t
i
f
i
e
d
 
S
N
P
.
 
B
o
l
d
e
d
 
r
o
w
s
 
i
n
d
i
c
a
t
e
 
p
r
e
d
i
c
t
e
d
 
g
e
n
e
s
 
c
o
n
s
i
d
e
r
e
d
 
a
s
 
n
o
n
-
c
o
d
i
n
g
 
r
e
g
i
o
n
s
 
b
y
 
N
e
x
t
G
E
N
e
 
S
o
f
t
w
a
r
e
(
S
o
f
t
G
e
n
e
t
i
c
s
)
.
 
+
S
N
P
 
i
d
e
n
t
i
f
i
e
d
 
b
y
 
S
a
n
g
e
r
 
s
e
q
u
e
n
c
i
n
g
 
a
s
 
h
e
t
e
r
o
z
y
g
o
u
s
 
a
n
d
 
b
y
 
n
e
x
t
-
g
e
n
e
r
a
t
i
o
n
 
r
e
s
e
q
u
e
n
c
i
n
g
 
a
s
 
h
o
m
o
z
y
g
o
u
s
.
 
M
a
n
u
a
l
 
r
e
a
d
i
n
g
 
o
f
 
s
e
q
u
e
n
c
e
s
 
g
e
n
e
r
a
t
e
d
b
y
 
n
e
x
t
-
g
e
n
e
r
a
t
i
o
n
 
r
e
s
e
q
u
e
n
c
i
n
g
 
d
e
m
o
n
s
t
r
a
t
e
d
 
2
 
r
e
a
d
s
 
w
i
t
h
 
a
 
G
u
a
n
i
n
e
 
a
n
d
 
3
2
 
r
e
a
d
s
 
w
i
t
h
 
C
y
t
o
s
i
n
e
 
a
t
 
b
a
s
e
 
n
u
m
b
e
r
 
1
,
4
1
0
 
o
f
 
C
2
0
o
r
f
1
2
.
 
*
S
N
P
 
l
o
c
a
t
e
d
 
i
n
 
a
 
r
e
g
i
o
n
 
t
h
a
t
w
a
s
 
n
o
t
 
a
d
e
q
u
a
t
e
l
y
 
c
o
v
e
r
e
d
 
(
l
e
s
s
 
t
h
a
n
 
5
 
r
e
a
d
s
)
 
b
y
 
N
G
S
.
 
*
*
 
C
o
v
e
r
a
g
e
 
w
a
s
 
a
d
e
q
u
a
t
e
 
t
o
 
i
d
e
n
t
i
f
y
 
v
a
r
i
a
n
t
 
(
b
e
t
w
e
e
n
 
5
 
a
n
d
 
2
0
 
r
e
a
d
s
)
,
 
b
u
t
 
w
a
s
 
i
n
s
u
f
f
i
c
i
e
n
t
 
t
o
 
p
r
o
d
u
c
e
 
a
m
u
t
a
t
i
o
n
 
c
a
l
l
 
s
c
o
r
e
 
o
f
 
≥
5
.
Molecular Vision 2010; 16:2829-2838 <http://www.molvis.org/molvis/v16/a303> © 2010 Molecular Vision
2835
T
A
B
L
E
 
3
.
 
S
E
Q
U
E
N
C
E
 
V
A
R
I
A
N
T
S
 
A
S
 
I
D
E
N
T
I
F
I
E
D
 
B
Y
 
S
A
N
G
E
R
 
S
E
Q
U
E
N
C
I
N
G
 
I
N
 
C
A
N
D
I
D
A
T
E
 
G
E
N
E
S
 
W
I
T
H
I
N
 
T
H
E
 
C
O
M
M
O
N
 
P
P
C
D
1
 
O
F
 
B
U
I
L
D
 
3
7
.
1
 
A
N
D
 
T
H
E
I
R
 
A
P
P
E
A
R
A
N
C
E
 
I
N
 
D
A
T
A
 
G
E
N
E
R
A
T
E
D
 
B
Y
 
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
S
E
Q
U
E
N
C
I
N
G
 
(
N
G
S
)
.
 
 
 
 
N
e
x
t
-
g
e
n
e
r
a
t
i
o
n
 
s
e
q
u
e
n
c
i
n
g
S
a
n
g
e
r
 
s
e
q
u
e
n
c
i
n
gIn the affected individual, 28 exonic sequence variants
were identified by Sanger sequencing in the 16 predicted
genes that map to the common PPCD1 interval, 9 (32%) of
which were identified with NGS, while the remaining 19 were
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pseudogene 3 [PTMAP3], ribosomal protein L21 pseudogene
3  [RPL21P3],  ribosomal  protein  S19  pseudogene  1
[RPS19P1],  and  double  homeobox  A  pseudogene  7
[DUXAP7]). In the unaffected individual, 25 exonic sequence
variants  were  identified  by  Sanger  sequencing  in  the  16
predicted genes, 6 (24%) of which were identified by NGS,
with the remaining 19 sequence variants not identified due to
insufficient  coverage  of  the  same  four  genes  that  were
insufficiently covered in the affected individual.
Similar percentages of exonic sequence variants were
identified  in  both  known  and  predicted  genes  with  NGS
compared to Sanger sequencing in the affected (25/45; 56%)
and unaffected (22/42; 52%) individuals. The 20 remaining
sequence variants were located in the same five genes in each
individual,  with  19  of  the  20  variants  common  to  each
individual.
Sequence analysis using best adjusted parameters without
Condensation  Tool:  By  adjusting  the  default  parameters
without the Condensation Tool (Table 2, Best Adjusted), we
were able to reduce the overall number of variants that were
identified while still detecting each of the exonic sequence
variants that had been identified by Sanger sequencing in the
29 genes in the common PPCD1 interval (provided there was
adequate coverage of the gene region). The adjustments that
were made were increasing the seed number (length of the
sequence that is used to match to the reference genome), the
move  step  (the  number  of  bases  between  the  seed  start
positions), the matching base percentage (the percentage of
reads that need to match to the reference genome for alignment
of the reads to the reference), and the mutation percentage (the
minimum percentage of reads in which a sequence variant
must  appear  before  being  consider  a  true  variant).  In  the
affected patient, 429,393 matched reads were obtained, in
which 46,090 DNA sequence variants were identified in the
common PPCD1 support interval. One hundred eighty-seven
(0.40%) of the variants were located in the coding regions of
the known and predicted genes, representing a 48% reduction
in the number of coding region variants when compared to the
number  identified  using  the  default  parameters.
Approximately  one-half  as  many  sequence  variants  were
identified in the 360,870 matched reads in the unaffected
individual  (23,090)  as  were  identified  in  the  affected
individual, representing a 33% reduction compared to the
number identified using the default parameters, 0.54% (125)
of which were coding region variants.
Increasing specificity: Filter by Mutation Score: In an attempt
to increase the stringency of the sequence variants identified
by NGS, we reported a mutation call score for each sequence
variant (Table 3). The mutation call score is a NextGENe
software-generated score based on a mathematical algorithm
that takes into consideration the level of coverage, the fraction
of  reads  with  the  mutation,  the  probability  of  mismatch
alignment, and potential false positive calls due to repeating
sequences of bases known as homopolymer errors. Although
SoftGenetics suggests a threshold mutation call score of 10,
we felt that this was too stringent for our data set and therefore
selected a threshold mutation call score of 5, which equates to
an approximately 70% chance of an identified variant being
real.  Using  the  best  adjusted  parameters  without  the
Condensation Tool, with a minimum overall mutation call
score of 5, 9,492 DNA sequence variants were identified in
the  common  PPCD1  support  interval  in  the  affected
individual, of which 0.57% (54) variants were located in the
coding regions of the 13 known genes. Each of the exonic
coding region variants previously identified by NGS using the
best adjusted parameters without the condensation tool were
still  identified  after  applying  this  additional  screening
criterion,  with  the  exception  of  c.846T>C  in  C20orf72
(inadequate  coverage,  4  reads).  Using  the  best  adjusted
parameters without the Condensation Tool, with a minimum
mutation call score of 5, 5,627 DNA sequence variants were
identified  in  the  common  PPCD1  support  interval  in  the
unaffected individual, of which 0.75% (42) variants were
located in the coding regions of the 13 known genes. Two
variants (c. 846T>C in C20orf72 and c.843C>T in PTMAP3)
that  were  identified  by  Sanger  sequencing  and  were  also
previously identified by NGS were not identified after the
application of a minimum mutation call score of 5.
DISCUSSION
The growing number of reports of the successful identification
of pathogenic variants in human disease genes by targeted
enrichment of a chromosomal locus followed by NGS are
evidence of the utility of NGS as an efficient, cost-effective
means to screen candidate genes [11,12,15]. While Sanger
sequencing  has  been  the  preferred  method  over  the  past
quarter-century for gene screening to identify a pathogenic
sequence variant, it is an expensive and inefficient means to
screen candidate loci that contain a moderate to large number
of genes. Therefore, we were interested in performing NGS
of a genetic region that had already been screened by Sanger
sequencing,  the  common  PPCD1  support  interval,  to
determine whether NGS could in fact identify all of the exonic
sequence  variants  that  had  been  previously  identified  by
Sanger sequencing.
Although  NGS  has  quickly  become  the  preferred
technique  among  researchers  for  SNP  identification,  we
identified  several  limitations  of  the  technology.  First,  to
identify all of the exonic variants in the common PPCD1
interval previously identified with Sanger sequencing, the
filter parameters may need to be adjusted from their default
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interval, we knew what sequence variants were present in the
selectively enriched chromosomal region a priori, and thus
adjusted the filter parameters until each of the variants in
regions of adequate coverage was identified. However, NGS
will typically be used to screen regions using patient DNA
samples that have not been previously sequenced, and thus
investigators will not be able to optimize the filter parameters
in the manner that we were.
Second,  NGS  was  effective  at  identifying  sequence
variants only in regions in which the coverage was adequate.
Factors  that  affect  coverage,  and  therefore  affect  the
likelihood of identifying a particular sequence variant, include
the efficacy of selective enrichment of the region in which the
variant is located, the sequencing efficiency of NGS (which
depends on the platform that is used) and the reliability of
sequence assembly and analysis [17]. A coverage simulation
that was performed to determine the quality of data that is
generated at various levels of coverage below the maximum
achieved level demonstrated that coverage of at least 40× was
necessary to achieve desirable SNP detection performance
[9]. We found that coverage of at least fivefold was adequate
to identify all of the variants previously identified with Sanger
sequencing  in  the  genes  of  the  common  PPCD1  support
interval.  However,  the  significantly  greater  number  of
sequence  variants  identified  in  the  affected  individual
compared to the unaffected individual is likely attributable at
least in part to the 15%–20% difference in the number of
matched reads to the reference sequence between the two
samples.
Third,  NGS  identified  many  more  exonic  sequence
variants  than  were  identified  by  Sanger  sequencing,
increasing the number of sequence variants that would need
to be evaluated further by screening affected and unaffected
individuals. To reduce the number of identified variants that
represent  false  positives,  we  applied  an  overall  mutation
quality score, in this case the NextGENe software mutation
score filter. Although the recommended threshold mutation
call score is 10, corresponding to a 1 out of 10 chance of a
variant being false, 6 of the 46 (13%) mutation call scores for
the variants that we identified were under 10, prompting us to
change the threshold to ≥5, which significantly reduced the
number of identified variants. However, one factor to consider
is  the  potential  loss  of  real  variants  due  to  increased
stringency: in our study, one variant identified by Sanger
sequencing in the affected patient and two variants identified
with Sanger sequencing in the unaffected patient that NGS
identified  using  the  best  adjusted  parameters  without  the
condensation tool were not identified when the mutation score
filter was applied. As the mutation call score is dependent to
large degree on the level of coverage, the failure to identify
these variants due to insufficient coverage highlights the fact
that this filter be used only in regions of sufficient coverage.
In conclusion, we report that NGS is able to reproduce
sequencing data generated through Sanger sequencing in a
significantly shorter period of time, and with far less expense.
As the NGS platforms continue to evolve, we expect that many
of  the  limitations  of  the  technology  that  researchers  face
currently will be resolved though improved sequence capture
and  sequencing  methods,  as  well  as  more  sophisticated
techniques of sequence assembly and analysis.
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